Business
Picard Medical / SynCardia Featured in Interview Series with The Mullings Group
– Discussions to highlight total artificial heart therapy, advanced heart failure market, and next-generation platform development – TUCSON, Ariz., April 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, announced today it has been featured in a two-part interview series with Joe Mulling
About this update from Picard Medical, Inc.
[{"type":"image","alt":"Picard Medical, Inc.","displaySize":"","headline":null,"caption":"Picard Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/4e25733b249cfcdd029f5354275c291a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MiFgFhEV9BOpmHkrZOmKRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNQ--/https://media.zenfs.com/en/globenewswire.com/4e25733b249cfcdd029f5354275c291a","width":300,"height":75}},"lazy":false},{"type":"text","content":"– Discussions to highlight total artificial heart therapy, advanced heart failure market, and next-generation platform development –","length":132,"tagName":"p"},{"type":"text","content":"TUCSON, Ariz., April 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, announced today it has been featured in a two-part interview series with Joe Mullings, Chairman and Chief Executive Officer of The Mullings Group Companies, a premier global executive search firm specialized in the MedTech, HealthTech, and Life Sciences industries. Filmed, edited, and produced by Dragonfly, A TMG Company, the series features an in-depth discussion with Picard Medical Chief Executive Officer, Patrick N.J. Schnegelsberg, focused on advanced heart failure and the role of total artificial heart technology in patients with end-stage biventricular failure.","length":856,"tagName":"p"},{"type":"text","content":"The discussions outline the clinical use of the SynCardia Total Artificial Heart, the only U.S. FDA-approved total artificial heart, which replaces the pumping function of the native heart, and is used as a bridge to transplant for patients awaiting donor organs. Mr. Schnegelsberg also highlights the Company’s innovation strategy, including development of its next generation fully implantable platform, the Emperor Total Artificial Heart, designed to improve patient mobility and expand access to therapy.","length":508,"tagName":"p"},{"type":"text","content":"“For patients with end-stage biventricular failure, total artificial heart therapy is often the only viable option,” Mr. Schnegelsberg emphasized during the first interview. “We are de...